TrialAssure offers academics free trial reporting tool

By Jenni Spinner contact

- Last updated on GMT

(Image: Getty/metamorworks)
(Image: Getty/metamorworks)

Related tags: Clinical trial, University, Clinical research services

The software company is offering institutions no-cost access to its registry clinical trial disclosure reporting application.

The vendor is enabling academic institutions to access TrialAssure Registry for no charge, including one upgrade per year. It includes registry configurations for and the US Food and Drug Administration (FDA) clinical trial registry.

Academic users that qualify for the subscription program can gain free access for up to two years. In exchange, the company asks participants to commit to full transparency in their research, including improvements to registry compliance, over that time period.

Need for prompt reporting

Mohamad Zahreddine, chief information officer for TrialAssure, said the company recognizes the need for more timely reporting of clinical trials, especially in the academic realm.

Our goal is to provide the tools to help where the need is most evident – in the academic setting​,” he said. “With our streamlined and intuitive registration and results posting capabilities, academic institutions will have the tools they need to achieve full compliance with applicable government requirements​.”       

While regulations issued by the US and other global health authorities call for registration and posting of clinical trial summary results, most trials fall short. According to the company, only about 34% of clinical trials sponsored by academic institutions and similar organizations report their results on time.

With the TrialAssure Registry program for academics, users will have up to three professional and 20 reviewer-level users at their disposal. Subscribers continue to own and manage their data directly and have access to full training documentation.

Additionally, there is no requirement for TrialAssure colleagues to intervene or conduct any activities on behalf of the subscriber. However, the subscriber may request such assistance.

Need for transparency

Kelly Vaillant, director of global transparency strategy and compliance for TriaAssure, said the company is offering the no-cost subscription program to help provide the data transparency necessary to help advance drug development.

As an industry, we have a responsibility and obligation to make information about clinical trials available in a way that protects the patient’s privacy but also allows for the benefits to science​,” Vaillant said. “If we can help organizations enhance transparency across their clinical research activities, which is needed, it’s a strong step in the right direction​.”

Academic institutions interested in applying for a free subscription are asked to do so before the October 7 deadline. The application is available on the TrialAssure website.

Related news

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more